文献速递消化、代谢与肾脏急症

移动聊天信息用于吸烟复吸预防:一项随机临床试验

Mobile Chat Messaging for Smoking Relapse Prevention: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在近期戒烟者中,常规戒烟服务加3个月移动聊天干预使6个月生化验证戒烟率从35.5%提高到45.9%(RR 1.29)。

该随机临床试验于2023年3月14日至2024年8月15日在香港2家诊所戒烟服务开展,纳入每日吸烟且已戒断3至30天的成年人590例,随机分为干预组294例和对照组296例。所有参与者接受常规戒烟治疗,干预组额外接受3个月移动复吸预防干预,包括真人辅导员聊天支持和通过消息应用访问支持性聊天机器人;对照组在3个月内接受8条通用戒烟建议短信作为接触对照。主要终点为随机化后6个月生化验证戒烟(呼气一氧化碳<5 ppm或唾液可替宁阴性),干预组45.9% vs 对照组35.5%(RR 1.29,95%CI 1.06-1.58,P=0.01)。干预组6个月 prolonged abstinence、7天时点戒烟率更高,复吸率更低。

要点

  • 在近期戒烟(3-30天)成人中,常规戒烟服务加3个月移动聊天干预使6个月生化验证戒烟率45.9% vs 35.5%(RR 1.29,95%CI 1.06-1.58)。
  • 干预组6个月 prolonged abstinence 57.5% vs 47.6%(RR 1.21,95%CI 1.03-1.41),7天时点戒烟率65.6% vs 54.7%(RR 1.20,95%CI 1.05-1.37)。
  • 干预组6个月复吸率(连续7天吸烟)33.0% vs 44.9%(RR 0.73,95%CI 0.60-0.90)。
  • 6个月随访保留率98.0%(578/590),意向性分析假设缺失结局者复吸。

适用人群与场景

  • 纳入每日吸烟且已戒断3至30天的成年人,来自香港2家诊所戒烟服务,随机化前接受常规戒烟治疗。

诊断标准与关键阈值

  • 生化验证戒烟:呼气一氧化碳水平<5 ppm或唾液可替宁检测阴性。
  • 复吸:连续7天吸烟。

处置流程与药物剂量

  • 所有参与者接受戒烟服务提供的常规戒烟治疗。
  • 干预组额外接受3个月移动复吸预防干预:由真人辅导员通过消息应用提供聊天支持,并可访问支持性聊天机器人。
  • 对照组在3个月内接受8条通用戒烟建议短信作为接触对照。

研究设计与关键结果

  • 随机临床试验,590例参与者(干预组294例,对照组296例),78.8%为男性,平均年龄47.1(SD 11.2)岁,在香港2家诊所戒烟服务开展。
  • 主要终点6个月生化验证戒断率:干预组45.9%(135/294)vs 对照组35.5%(105/296),RR 1.29(95%CI 1.06-1.58),P=0.01。
  • 6个月 prolonged abstinence:干预组57.5%(169/294)vs 对照组47.6%(141/296),RR 1.21(95%CI 1.03-1.41),P=0.02。
  • 6个月7天时点戒烟率:干预组65.6%(193/294)vs 对照组54.7%(162/296),RR 1.20(95%CI 1.05-1.37),P=0.007。
  • 6个月复吸率:干预组33.0%(97/294)vs 对照组44.9%(133/296),RR 0.73(95%CI 0.60-0.90),P=0.003。
  • 6个月随访保留率98.0%(n=578)。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,移动聊天信息用于吸烟复吸预防使验证戒断率增加约30%,为近期戒烟者维持戒断提供了一种可扩展的方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Most individuals attempting smoking cessation relapse, even with evidence-based treatment. Mobile interventions offer a potential but largely untested strategy to sustain cessation.

OBJECTIVE: To test the effectiveness of mobile chat messaging for relapse prevention among individuals who recently quit smoking.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted from March 14, 2023, to August 15, 2024, at 2 clinic-based smoking cessation services in Hong Kong. Participants were adults who smoked daily and had abstained for 3 to 30 days; they were randomly assigned to an intervention group or a control group.

INTERVENTIONS: All participants received usual smoking cessation treatment from the services. The intervention group additionally received 3 months of mobile relapse prevention intervention, including chat-based support delivered by a live counselor and access to a supportive chatbot via a messaging app. The control group received 8 text messages on generic smoking cessation advice over 3 months as a contact control.

MAIN OUTCOMES AND MEASURES: The primary outcome was biochemically validated tobacco abstinence at 6 months after randomization, defined by an exhaled carbon monoxide level of less than 5 ppm or a negative salivary cotinine test result. Secondary outcomes at 6 months included self-reported prolonged abstinence, 7-day point prevalence abstinence, and relapse (7 consecutive days of smoking) rate. Intention-to-treat analyses were conducted, assuming participants with missing outcomes relapsed.

RESULTS: Of 590 participants, 465 (78.8%) were male, and the mean (SD) age was 47.1 (11.2) years; 294 were randomized to the intervention group and 296 were randomized to the control group. The retention rate at 6-month follow-up was 98.0% (n = 578). Biochemically validated abstinence at 6 months was significantly higher in the intervention group than in the control group (45.9% [135 of 294] vs 35.5% [105 of 296]; relative risk [RR], 1.29; 95% CI, 1.06-1.58; P = .01). The intervention group also reported significantly higher prolonged abstinence (57.5% [169 of 294] vs 47.6% [141 of 296]; RR, 1.21; 95% CI, 1.03-1.41; P = .02), higher 7-day point prevalence abstinence (65.6% [193 of 294] vs 54.7% [162 of 296]; RR, 1.20; 95% CI, 1.05-1.37; P = .007), and lower relapse rate (33.0% [97 of 294] vs 44.9% [133 of 296]; RR, 0.73; 95% CI, 0.60-0.90; P = .003) at 6 months.

CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that mobile chat messaging for smoking relapse prevention increased validated abstinence by approximately 30%, offering a scalable approach to sustain abstinence among individuals who recently quit smoking.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05370352.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Luk TT, Su X, Wong V, et al. Mobile Chat Messaging for Smoking Relapse Prevention: A Randomized Clinical Trial. JAMA Intern Med. 2026. PMID: 41557345. doi:10.1001/jamainternmed.2025.7439

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。